Ignite Creation Date:
2025-12-24 @ 12:48 PM
Ignite Modification Date:
2026-02-20 @ 1:35 PM
Study NCT ID:
NCT02811861
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-11-01
First Post:
2016-06-21
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Sponsor:
Eisai Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Renal Cell Carcinoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Renal Cell Carcinoma (RCC) | View |
| None | Lenvatinib | View |
| None | First-line RCC | View |
| None | Treatment-naive RCC | View |
| None | Everolimus | View |
| None | Pembrolizumab | View |
| None | Sunitinib | View |
| None | Phase 3 RCC | View |
| None | Phase 3 first-line RCC | View |
| None | Phase 3 treatment-naive RCC | View |